CHDR Enrolls 500th Psoriasis Patient in Clinical Trials
28 October 2025
CHDR has reached a major milestone in dermatology research: the enrollment of our 500th psoriasis patient across clinical trials, marking eight years of innovation and collaboration in advancing treatment options.
Today, CHDR celebrates a significant achievement in our dermatology research journey: the enrollment of our 500th psoriasis patient in clinical trials. This milestone reflects years of dedication to patient-centric research and proof-of-concept innovation.
Over the past eight years, CHDR has successfully conducted 12 clinical trials in psoriasis, including Phase 0, Phase 1, and Phase 2 studies. Each trial has contributed to a deeper understanding of the disease and the development of new therapeutic strategies.
This achievement is a testament to:
The patients who participate with trust and commitment
The incredible teamwork of our recruiters, clinicians, dermatologists, technologists, and scientists
The support of Psoriasispatiënten Nederland and our Dutch trial network
Our shared dedication to advancing dermatology research
We are proud to continue this momentum and will celebrate further during the 50th anniversary of Psoriasispatiënten Nederland at Royal Jaarbeurs Utrecht this weekend.
Thank you to everyone who made this possible. Together, we move forward in our mission: to develop better medicines for patients.